Results 41 to 50 of about 35,072 (188)

Long-term follow-up of patients with uveitis treated with adalimumab: response rates and reasons for discontinuation of therapy.

American journal of ophthalmology-glaucoma, 2022
PURPOSE To evaluate the effectiveness and reasons for discontinuation including the side effect profiles of adalimumab in a real-world setting. DESIGN A retrospective clinical cohort study was performed.
L. Eurelings, T. Missotten, M. V. van Velthoven, P. V. van Daele, J. V. van Laar, P. V. van Hagen, A. Thiadens, S. Rombach   +7 more
semanticscholar   +1 more source

Adalimumab Monotherapy in the Treatment of Idiopathic Multifocal Choroiditis: A Case Report

Case Reports in Ophthalmology, 2022
In this study, we report a case of multifocal choroiditis that was successfully treated with adalimumab monotherapy. A 25-year-old male presented with a history of bilateral multifocal choroiditis which was resistant to a combination of azathioprine ...
Arash Maleki, Andrew Philip, C. Stephen Foster   +2 more
doaj   +1 more source

Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn’s disease

World Journal of Gastroenterology, 2022
BACKGROUND Tumor necrosis factor-alpha inhibitors, including infliximab and adalimumab, are effective medical treatments for perianal fistulising Crohn’s disease (CD), but not all patients achieve fistula healing. AIM To determine the correlation between
B. Gu, K. Venkatesh, A. Williams, W. Ng, C. Corte, A. Gholamrezaei, S. Ghaly, W. Xuan, S. Paramsothy, S. Connor   +9 more
semanticscholar   +1 more source

Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double‐blind, parallel‐controlled, phase 1 study

Pharmacology Research & Perspectives, 2021
The primary objective of this randomized, double‐blind, parallel‐controlled study (from December 2016 to October 2018) was to evaluate pharmacokinetic (PK) equivalence of adalimumab biosimilar HLX03 and reference adalimumab in healthy volunteers, and to ...
Hong Zhang, Min Wu, Jixuan Sun, Xiaoxue Zhu, Cuiyun Li, Yanhua Ding, Xiaodi Zhang, Katherine Chai, Xiaojiao Li   +8 more
doaj   +1 more source

Effect of Secukinumab Versus Adalimumab Biosimilar on Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: Results From a Head‐to‐Head Randomized Phase IIIb Study

Arthritis & Rheumatology
Spinal radiographic progression is an important outcome in radiographic axial spondyloarthritis (SpA). The objective of the phase IIIb SURPASS study was to compare spinal radiographic progression in patients with radiographic axial SpA treated with ...
X. Baraliakos, Mikkel Østergaard, Denis Poddubnyy, D. van der Heijde, A. Deodhar, Pedro M. Machado, V. Navarro-Compán, Kay-Geert A Hermann, M. Kishimoto, Eun Young Lee, L. Gensler, U. Kiltz, M. Eigenmann, P. Pertel, A. Readie, H. Richards, B. Porter, J. Braun   +17 more
semanticscholar   +1 more source

Can adalimumab prevent from acute effects of lipopolysaccharide induced renal injury in rats? [PDF]

Acta Cirúrgica Brasileira
Purpose: Lipopolysaccharides is well-known in the acute renal injury process. It causes widespread activation of inflammatory cascades. Tumor necrosis factor (TNF)-α and interleukin (Il)-6 are essential proinflammatory cytokines that can induce the ...
Nuket Özkavruk Eliyatkın, Akif İşlek, Selim Durmaz, Fevzi Ayyıldız, Ömer Rahman   +4 more
doaj   +1 more source

Efficacy and safety of guselkumab, an anti‐interleukin‐23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double‐blind, placebo‐ and active comparator–controlled VOYA

Journal of American Academy of Dermatology, 2017
Background: Phase II data suggested that guselkumab, an anti‐interleukin‐23 monoclonal antibody, was efficacious in psoriasis. Objective: We sought to assess efficacy and safety of guselkumab in moderate to severe psoriasis versus placebo and adalimumab,
K. Reich, A. Armstrong, P. Foley, Michael Song, Y. Wasfi, B. Randazzo, Shu Li, Y.K. Shen, K. Gordon   +8 more
semanticscholar   +1 more source

Evidence for a ‘window of opportunity’ in hidradenitis suppurativa treated with adalimumab: a retrospective, real‐life multicentre cohort study *

British Journal of Dermatology, 2020
The anti‐tumour necrosis factor (TNF)‐α adalimumab is the only licenced biologic for moderate‐to‐severe hidradenitis suppurativa (HS). No predictors of response have been identified so far.
A. Marzano, A. Marzano, G. Genovese, G. Genovese, G. Casazza, C. Moltrasio, C. Moltrasio, P. Dapavo, G. Micali, R. Sirna, P. Gisondi, A. Patrizi, V. Dini, D. Bianchini, L. Bianchi, L. Fania, F. Prignano, A. Offidani, L. Atzori, V. Bettoli, S. P. Cannavò, M. Venturini, M. Bongiorno, A. Costanzo, G. Fabbrocini, K. Peris   +25 more
semanticscholar   +1 more source

Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa

Journal of Clinical Medicine, 2022
Adalimumab is currently the only biological medicine approved by the FDA for the treatment of hidradenitis suppurativa (HS). The breakout of biosimilar drugs made them more accessible due to their impact on pharmacoeconomics.
T. Montero‐Vilchez, C. Cuenca-Barrales, A. Rodríguez-Tejero, A. Martínez-López, S. Arias-Santiago, A. Molina‐Leyva   +5 more
semanticscholar   +1 more source

A Rare Side Effect due to TNF-Alpha Blocking Agent: Acute Pleuropericarditis with Adalimumab

Case Reports in Rheumatology, 2013
Tumor necrosis factor-alpha antagonism is an important treatment strategy in patients with rheumatoid arthritis, psoriatic arthritis, vasculitis, and ankylosing spondylitis. Adalimumab is one of the well-known tumor necrosis factor-alpha blocking agents.
Hakan Ozkan, Ahmet Seckin Cetinkaya, Tekin Yildiz, Tahsin Bozat   +3 more
doaj   +1 more source